Fat distribution and weight gain -
To date, more than different genes have been implicated in the causes of overweight or obesity, although only a handful appear to be major players. Genes contribute to the causes of obesity in many ways, by affecting appetite, satiety the sense of fullness , metabolism, food cravings, body-fat distribution, and the tendency to use eating as a way to cope with stress.
The strength of the genetic influence on weight disorders varies quite a bit from person to person. Having a rough idea of how large a role genes play in your weight may be helpful in terms of treating your weight problems.
Genes are probably a significant contributor to your obesity if you have most or all of the following characteristics:. Genes are probably a lower contributor for you if you have most or all of the following characteristics:.
These circumstances suggest that you have a genetic predisposition to be heavy, but it's not so great that you can't overcome it with some effort.
At the other end of the spectrum, you can assume that your genetic predisposition to obesity is modest if your weight is normal and doesn't increase even when you regularly indulge in high-calorie foods and rarely exercise.
People with only a moderate genetic predisposition to be overweight have a good chance of losing weight on their own by eating fewer calories and getting more vigorous exercise more often. These people are more likely to be able to maintain this lower weight.
When the prey escaped or the crops failed, how did our ancestors survive? Those who could store body fat to live off during the lean times lived, and those who couldn't, perished.
Today, of course, these thrifty genes are a curse rather than a blessing. Not only is food readily available to us nearly around the clock, we don't even have to hunt or harvest it! In contrast, people with a strong genetic predisposition to obesity may not be able to lose weight with the usual forms of diet and exercise therapy.
Even if they lose weight, they are less likely to maintain the weight loss. For people with a very strong genetic predisposition, sheer willpower is ineffective in counteracting their tendency to be overweight. Typically, these people can maintain weight loss only under a doctor's guidance.
They are also the most likely to require weight-loss drugs or surgery. The prevalence of obesity among adults in the United States has been rising since the s. Genes alone cannot possibly explain such a rapid rise.
Although the genetic predisposition to be overweight varies widely from person to person, the rise in body mass index appears to be nearly universal, cutting across all demographic groups. These findings underscore the importance of changes in our environment that contribute to the epidemic of overweight and obesity.
Genetic factors are the forces inside you that help you gain weight and stay overweight; environmental factors are the outside forces that contribute to these problems. They encompass anything in our environment that makes us more likely to eat too much or exercise too little.
Taken together, experts think that environmental factors are the driving force for the causes of obesity and its dramatic rise. Environmental influences come into play very early, even before you're born.
Researchers sometimes call these in-utero exposures "fetal programming. The same is true for babies born to mothers who had diabetes. Researchers believe these conditions may somehow alter the growing baby's metabolism in ways that show up later in life.
After birth, babies who are breast-fed for more than three months are less likely to have obesity as adolescents compared with infants who are breast-fed for less than three months.
Childhood habits often stick with people for the rest of their lives. Kids who drink sugary sodas and eat high-calorie, processed foods develop a taste for these products and continue eating them as adults, which tends to promote weight gain. Likewise, kids who watch television and play video games instead of being active may be programming themselves for a sedentary future.
Many features of modern life promote weight gain. In short, today's "obesogenic" environment encourages us to eat more and exercise less. And there's growing evidence that broader aspects of the way we live — such as how much we sleep, our stress levels, and other psychological factors — can affect weight as well.
According to the Centers for Disease Control and Prevention CDC , Americans are eating more calories on average than they did in the s. Between and , the average man added calories to his daily fare, while the average woman added calories a day.
What's driving this trend? Experts say it's a combination of increased availability, bigger portions, and more high-calorie foods. Practically everywhere we go — shopping centers, sports stadiums, movie theaters — food is readily available.
You can buy snacks or meals at roadside rest stops, hour convenience stores, even gyms and health clubs. In the s, fast-food restaurants offered one portion size. Today, portion sizes have ballooned, a trend that has spilled over into many other foods, from cookies and popcorn to sandwiches and steaks.
A typical serving of French fries from McDonald's contains three times more calories than when the franchise began. A single "super-sized" meal may contain 1,—2, calories — all the calories that most people need for an entire day. And research shows that people will often eat what's in front of them, even if they're already full.
Not surprisingly, we're also eating more high-calorie foods especially salty snacks, soft drinks, and pizza , which are much more readily available than lower-calorie choices like salads and whole fruits.
Fat isn't necessarily the problem; in fact, research shows that the fat content of our diet has actually gone down since the early s. But many low-fat foods are very high in calories because they contain large amounts of sugar to improve their taste and palatability.
In fact, many low-fat foods are actually higher in calories than foods that are not low fat. The government's current recommendations for exercise call for an hour of moderate to vigorous exercise a day. Our daily lives don't offer many opportunities for activity.
Obesity index that better predict metabolic syndrome: body mass index, waist circumference, waist hip ratio, or waist height ratio.
J Obes ; : Article Google Scholar. Pischon T, Boeing H, Hoffmann K, Bergmann M, Schulze MB, Overvad K et al. General and abdominal adiposity and risk of death in Europe.
N Engl J Med ; : — Shungin D, Winkler TW, Croteau-Chonka DC, Ferreira T, Locke AE, Magi R et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature ; : — Svendstrup M, Sandholt CH, Andersson Galijatovic EA, Linneberg A, Jorgensen T, Sorensen TI et al.
Genetic risk scores link body fat distribution with specific cardiometabolic profiles. Obesity Silver Spring ; 24 : — Emdin CA, Khera AV, Natarajan P, Klarin D, Zekavat SM, Hsiao AJ et al.
Genetic association of waist-to-hip ratio with cardiometabolic traits, type 2 diabetes, and coronary heart disease.
JAMA ; : — Scott RA, Fall T, Pasko D, Barker A, Sharp SJ, Arriola L et al. Common genetic variants highlight the role of insulin resistance and body fat distribution in type 2 diabetes, independently of obesity.
Diabetes ; 63 : — Lotta LA, Gulati P, Day FR, Payne F, Ongen H, van de Bunt M et al. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance.
Nat Genet ; 49 : 17— Dale CE, Fatemifar G, Palmer TM, White J, Prieto-Merino D, Zabaneh D et al. Causal associations of adiposity and body fat distribution with coronary heart disease, stroke subtypes, and type 2 diabetes mellitus: a Mendelian randomization analysis.
Circulation ; : — Yates A, Akanni W, Amode MR, Barrell D, Billis K, Carvalho-Silva D et al. Ensembl Nucleic Acids Res ; 44 : D—D Brakenhielm E, Cao R, Gao B, Angelin B, Cannon B, Parini P et al. Angiogenesis inhibitor, TNP, prevents diet-induced and genetic obesity in mice.
Circ Res ; 94 : — Sun K, Kusminski CM, Scherer PE. Adipose tissue remodeling and obesity. J Clin Invest ; : — Sun K, Wernstedt Asterholm I, Kusminski CM, Bueno AC, Wang ZV, Pollard JW et al.
Dichotomous effects of VEGF-A on adipose tissue dysfunction. Proc Natl Acad Sci USA ; : — Cao Y. Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases. Nat Rev Drug Discov ; 9 : — Angiogenesis modulates adipogenesis and obesity.
Rupnick MA, Panigrahy D, Zhang CY, Dallabrida SM, Lowell BB, Langer R et al. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci USA ; 99 : — Divoux A, Tordjman J, Lacasa D, Veyrie N, Hugol D, Aissat A et al. Fibrosis in human adipose tissue: composition, distribution, and link with lipid metabolism and fat mass loss.
Diabetes ; 59 : — Bel Lassen P, Charlotte F, Liu Y, Bedossa P, le Naour G, Tordjman J et al. The FAT score, a Fibrosis score of Adipose Tissue: predicting weight loss outcome after gastric bypass.
J Clin Endocrinol Metab ; : — Sethi JK, Vidal-Puig AJ. Thematic review series: adipocyte biology. Adipose tissue function and plasticity orchestrate nutritional adaptation.
J Lipid Res ; 48 : — Virtue S, Vidal-Puig A. Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome—an allostatic perspective. Biochim Biophys Acta ; : — It's not how fat you are, it's what you do with it that counts.
PLoS Biol ; 6 : e Frayn KN. Adipose tissue as a buffer for daily lipid flux. Diabetologia ; 45 : — Tan CY, Vidal-Puig A. Adipose tissue expandability: the metabolic problems of obesity may arise from the inability to become more obese.
Biochem Soc Trans ; 36 Pt 5 : — Taylor R, Holman RR. Normal weight individuals who develop type 2 diabetes: the personal fat threshold. Clin Sci Lond ; : — Kong LC, Wuillemin PH, Bastard JP, Sokolovska N, Gougis S, Fellahi S et al.
Insulin resistance and inflammation predict kinetic body weight changes in response to dietary weight loss and maintenance in overweight and obese subjects by using a Bayesian network approach. Am J Clin Nutr ; 98 : — Campos GM, Rabl C, Mulligan K, Posselt A, Rogers SJ, Westphalen AC et al.
Factors associated with weight loss after gastric bypass. Daumit GL, Goff DC, Meyer JM, Davis VG, Nasrallah HA, McEvoy JP, Rosenheck R, Davis SM, Hsiao JK, Stroup TS, Lieberman JA. Antipsychotic effects on estimated year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res.
Alvarez-Jimenez M, Hetrick SE, Gonzalez-Blanch C, Gleeson JF, McGorry PD. Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials.
The British journal of psychiatry : the journal of mental science. Mukundan A, Faulkner G, Cohn T, Remington G. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.
The Cochrane database of systematic reviews. Gierisch JM, Nieuwsma JA, Bradford DW, Wilder CM, Mann-Wrobel MC, McBroom AJ, Wing L, Musty MD, Chobot MM, Hasselblad V, Williams JW, Jr.
AHRQ Comparative Effectiveness Reviews. Interventions To Improve Cardiovascular Risk Factors in People With Serious Mental Illness. Rockville MD : Agency for Healthcare Research and Quality US ; Mizuno Y, Suzuki T, Nakagawa A, Yoshida K, Mimura M, Fleischhacker WW, Uchida H. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis.
Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis.
Zheng W, Li XB, Tang YL, Xiang YQ, Wang CY, de Leon J. Metformin for Weight Gain and Metabolic Abnormalities Associated With Antipsychotic Treatment: Meta-Analysis of Randomized Placebo-Controlled Trials.
Hu Y, Young AJ, Ehli EA, Nowotny D, Davies PS, Droke EA, Soundy TJ, Davies GE. Metformin and berberine prevent olanzapine-induced weight gain in rats. PloS one. Ebdrup BH, Knop FK, Ishoy PL, Rostrup E, Fagerlund B, Lublin H, Glenthoj B.
Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits. BMC Med. Lykkegaard K, Larsen PJ, Vrang N, Bock C, Bock T, Knudsen LB. The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance.
Sharma AN, Ligade SS, Sharma JN, Shukla P, Elased KM, Lucot JB. GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats.
Metab Brain Dis. Larsen JR, Vedtofte L, Jakobsen MSL, Jespersen HR, Jakobsen MI, Svensson CK, Koyuncu K, Schjerning O, Oturai PS, Kjaer A, Nielsen J, Holst JJ, Ekstrom CT, Correll CU, Vilsboll T, Fink-Jensen A. Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial.
JAMA psychiatry. Gross C, Blasey CM, Roe RL, Belanoff JK. Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men. Obesity Silver Spring.
Rimessi A, Pavan C, Ioannidi E, Nigro F, Morganti C, Brugnoli A, Longo F, Gardin C, Ferroni L, Morari M, Vindigni V, Zavan B, Pinton P. Protein Kinase C beta: a New Target Therapy to Prevent the Long-Term Atypical Antipsychotic-Induced Weight Gain.
Capuron L, Lasselin J, Castanon N. Role of Adiposity-Driven Inflammation in Depressive Morbidity. Muller N. COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence. Current opinion in investigational drugs London, England : Ben-Menachem E. Weight issues for people with epilepsy--a review.
Verrotti A, D'Egidio C, Mohn A, Coppola G, Chiarelli F. Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications.
Obes Rev. Belcastro V, D'Egidio C, Striano P, Verrotti A. Metabolic and endocrine effects of valproic acid chronic treatment. Epilepsy Res. Aycicek A, Iscan A. The effects of carbamazepine, valproic acid and phenobarbital on the oxidative and antioxidative balance in epileptic children.
Eur Neurol. Wong HY, Chu TS, Lai JC, Fung KP, Fok TF, Fujii T, Ho YY. Sodium valproate inhibits glucose transport and exacerbates Glut1-deficiency in vitro.
J Cell Biochem. Farinelli E, Giampaoli D, Cenciarini A, Cercado E, Verrotti A. Valproic acid and nonalcoholic fatty liver disease: A possible association? World J Hepatol.
Swann AC. Major system toxicities and side effects of anticonvulsants. Antel J, Hebebrand J. Weight-reducing side effects of the antiepileptic agents topiramate and zonisamide.
Handb Exp Pharmacol. Smith SM, Meyer M, Trinkley KE. The Annals of pharmacotherapy. Curtis JR, Westfall AO, Allison J, Bijlsma JW, Freeman A, George V, Kovac SH, Spettell CM, Saag KG.
Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis and rheumatism. Christ-Crain M, Kola B, Lolli F, Fekete C, Seboek D, Wittmann G, Feltrin D, Igreja SC, Ajodha S, Harvey-White J, Kunos G, Muller B, Pralong F, Aubert G, Arnaldi G, Giacchetti G, Boscaro M, Grossman AB, Korbonits M.
AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology. Larsen PJ, Jessop DS, Chowdrey HS, Lightman SL, Mikkelsen JD. Chronic administration of glucocorticoids directly upregulates prepro-neuropeptide Y and Y1-receptor mRNA levels in the arcuate nucleus of the rat.
J Neuroendocrinol. Harfstrand A, Cintra A, Fuxe K, Aronsson M, Wikstrom AC, Okret S, Gustafsson JA, Agnati LF. Regional differences in glucocorticoid receptor immunoreactivity among neuropeptide Y immunoreactive neurons of the rat brain.
Acta Physiol Scand. Soumano K, Desbiens S, Rabelo R, Bakopanos E, Camirand A, Silva JE. Glucocorticoids inhibit the transcriptional response of the uncoupling protein-1 gene to adrenergic stimulation in a brown adipose cell line.
Molecular and cellular endocrinology. Bowles NP, Karatsoreos IN, Li X, Vemuri VK, Wood JA, Li Z, Tamashiro KL, Schwartz GJ, Makriyannis AM, Kunos G, Hillard CJ, McEwen BS, Hill MN. A peripheral endocannabinoid mechanism contributes to glucocorticoid-mediated metabolic syndrome. Proc Natl Acad Sci U S A.
Fardet L, Feve B. Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events. Fardet L, Cabane J, Lebbe C, Morel P, Flahault A.
Incidence and risk factors for corticosteroid-induced lipodystrophy: a prospective study. J Am Acad Dermatol. Dube S, Slama MQ, Basu A, Rizza RA, Basu R.
Glucocorticoid Excess Increases Hepatic 11beta-HSD-1 Activity in Humans: Implications in Steroid-Induced Diabetes. Wolf G. Glucocorticoids in adipocytes stimulate visceral obesity. Nutr Rev.
Karatasakis A, Danek BA, Karacsonyi J, Rangan BV, Roesle MK, Knickelbine T, Miedema MD, Khalili H, Ahmad Z, Abdullah S, Banerjee S, Brilakis ES. Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 35 Randomized Controlled Trials.
J Am Heart Assoc. Baragetti A, Balzarotti G, Grigore L, Pellegatta F, Guerrini U, Pisano G, Fracanzani AL, Fargion S, Norata GD, Catapano AL.
PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans. Eur J Prev Cardiol. PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.
Norata GD, Tavori H, Pirillo A, Fazio S, Catapano AL. Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.
Cardiovasc Res. Roubtsova A, Munkonda MN, Awan Z, Marcinkiewicz J, Chamberland A, Lazure C, Cianflone K, Seidah NG, Prat A. Arterioscler Thromb Vasc Biol. Wierzbicki AS, Viljoen A. Anti-sense oligonucleotide therapies for the treatment of hyperlipidaemia. Expert Opin Biol Ther.
Hashemi N, Odze RD, McGowan MP, Santos RD, Stroes ES, Cohen DE. Liver histology during Mipomersen therapy for severe hypercholesterolemia.
J Clin Lipidol. Berberich AJ, Hegele RA. Lomitapide for the treatment of hypercholesterolemia. Expert Opin Pharmacother.
Alger HM, Brown JM, Sawyer JK, Kelley KL, Shah R, Wilson MD, Willingham MC, Rudel LL. Inhibition of acyl-coenzyme A:cholesterol acyltransferase 2 ACAT2 prevents dietary cholesterol-associated steatosis by enhancing hepatic triglyceride mobilization.
J Biol Chem. Meuwese MC, Franssen R, Stroes ES, Kastelein JJ. And then there were acyl coenzyme A:cholesterol acyl transferase inhibitors. Current opinion in lipidology. Chen D, Misra A, Garg A. Clinical review Lipodystrophy in human immunodeficiency virus-infected patients.
Mirza FS, Luthra P, Chirch L. Endocrinological aspects of HIV infection. Hulgan T, Haubrich R, Riddler SA, Tebas P, Ritchie MD, McComsey GA, Haas DW, Canter JA.
European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A de Waal R, Cohen K, Maartens G.
Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction. McComsey GA, Moser C, Currier J, Ribaudo HJ, Paczuski P, Dube MP, Kelesidis T, Rothenberg J, Stein JH, Brown TT. Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG As.
Clin Infect Dis. Erlandson KM, Lake JE. Fat Matters: Understanding the Role of Adipose Tissue in Health in HIV Infection. Scherzer R, Heymsfield SB, Lee D, Powderly WG, Tien PC, Bacchetti P, Shlipak MG, Grunfeld C. Study of Fat R, Metabolic Change in HIVI.
Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection. Lundgren JD, Battegay M, Behrens G, De Wit S, Guaraldi G, Katlama C, Martinez E, Nair D, Powderly WG, Reiss P, Sutinen J, Vigano A, Committee EE.
European AIDS Clinical Society EACS guidelines on the prevention and management of metabolic diseases in HIV. HIV Med. Caron-Debarle M, Lagathu C, Boccara F, Vigouroux C, Capeau J.
HIV-associated lipodystrophy: from fat injury to premature aging. Trends in molecular medicine. Giralt M, Domingo P, Guallar JP, Rodriguez de la Concepcion ML, Alegre M, Domingo JC, Villarroya F. Antiviral therapy.
Koczor CA, Lewis W. Nucleoside reverse transcriptase inhibitor toxicity and mitochondrial DNA. Expert Opin Drug Metab Toxicol.
Giralt M, Domingo P, Villarroya F. Adipose tissue biology and HIV-infection. Best Pract Res Clin Endocrinol Metab. Flint OP, Noor MA, Hruz PW, Hylemon PB, Yarasheski K, Kotler DP, Parker RA, Bellamine A.
The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications. Toxicol Pathol. Diaz-Delfin J, del Mar Gutierrez M, Gallego-Escuredo JM, Domingo JC, Gracia Mateo M, Villarroya F, Domingo P, Giralt M.
Effects of nevirapine and efavirenz on human adipocyte differentiation, gene expression, and release of adipokines and cytokines. Antiviral research. Hruz PW. Molecular mechanisms for insulin resistance in treated HIV-infection. Rietschel P, Hadigan C, Corcoran C, Stanley T, Neubauer G, Gertner J, Grinspoon S.
Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. Dube MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, Henry WK, Currier JS, Sprecher D, Glesby MJ. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus HIV -infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Schmitz M, Michl GM, Walli R, Bogner J, Bedynek A, Seidel D, Goebel FD, Demant T. Alterations of apolipoprotein B metabolism in HIV-infected patients with antiretroviral combination therapy. J Acquir Immune Defic Syndr.
Herink M, Ito MK. Medication Induced Changes in Lipid and Lipoproteins. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, Purnell J, Rebar R, Singer F, Vinik A, eds. Martin A, Smith DE, Carr A, Ringland C, Amin J, Emery S, Hoy J, Workman C, Doong N, Freund J, Cooper DA.
Mitochondrial Toxicity Study G. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. Norwood J, Turner M, Bofill C, Rebeiro P, Shepherd B, Bebawy S, Hulgan T, Raffanti S, Haas DW, Sterling TR, Koethe JR.
Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens. Rochira V, Guaraldi G.
Growth hormone deficiency and human immunodeficiency virus. Edgeworth A, Treacy MP, Hurst TP. AIDS Rev. Raboud JM, Diong C, Carr A, Grinspoon S, Mulligan K, Sutinen J, Rozenbaum W, Cavalcanti RB, Wand H, Costagliola D, Walmsley S.
Glitazone, Lipoatrophy Meta-Analysis Working G. A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy. HIV Clin Trials. Amouyal C, Buyse M, Lucas-Martini L, Hirt D, Genser L, Torcivia A, Bouillot JL, Oppert JM, Aron-Wisnewsky J. Sleeve Gastrectomy in Morbidly Obese HIV Patients: Focus on Anti-retroviral Treatment Absorption After Surgery.
Obesity surgery. Tsoukas MA, Farr OM, Mantzoros CS. Leptin in congenital and HIV-associated lipodystrophy. Jagdeo J, Ho D, Lo A, Carruthers A. A systematic review of filler agents for aesthetic treatment of HIV facial lipoatrophy FLA. Copyright © , MDText. Bookshelf ID: NBK PMID: PubReader Print View Cite this Page Verhaegen AA, Van Gaal LF.
Drugs That Affect Body Weight, Body Fat Distribution, and Metabolism. In: Feingold KR, Anawalt B, Blackman MR, et al. In this Page. Links to www. View this chapter in Endotext. Related information. PMC PubMed Central citations. Similar articles in PubMed.
Review Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options.
Epub Jun Review Drugs Affecting Body Weight, Body Fat Distribution, and Metabolic Function-Mechanisms and Possible Therapeutic or Preventive Measures: an Update.
Curr Obes Rep. Epub Jan 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K, Williams J, Qi YP, Gutman J, Yeung L, Mai C, Finkelstain J, Mehta S, Pons-Duran C, Menéndez C, et al.
Cochrane Database Syst Rev. Epub Feb 1. Review Diabetes in People Living with HIV. Sarkar S, Brown TT. Review Thin Fat Obesity: The Tropical Phenotype of Obesity. Kapoor N. Recent Activity. Clear Turn Off Turn On. Drugs That Affect Body Weight, Body Fat Distribution, and Metabolism - Endotext.
Follow NCBI. Twitter Facebook LinkedIn GitHub NCBI Insights Blog. Connect with NLM Twitter Facebook Youtube. NLM NIH HHS USA. Tricyclic agents. amitriptylline nortriptylline imipramine desipramine dosulepine doxepine clomipramine.
paroxetine citalopram fluoxetine sertraline. duloxetin venlafaxin. bupropion reboxetine. trazodone nefazodone. mirtazapine maprotiline mianserine. haloperidol perphenazine. aripiprazol ziprasidone lurasidone paliperidone iloperidone asenapine.
amisulpiride quietiapine risperidone sertindole. clozapine olanzapine. topiramate zonisamide. lamotrigine levtiracetam Tiagabine oxcarbazepine.
New research shows little andd of Garcinia cambogia for sale from prostate Fat distribution and weight gain. Discrimination distrkbution work is linked diztribution high blood pressure. Icy fingers ddistribution toes: Poor circulation or Raynaud's phenomenon? Everyone knows some people who can eat ice cream, cake, and whatever else they want and still not gain weight. At the other extreme are people who seem to gain weight no matter how little they eat. What are the causes of obesity?Fat distribution and weight gain -
A significant association was observed between body weight and both subcutaneous adipose tissue and total adipose tissue. A regain of body weight of 7. The increase observed in subcutaneous adipose tissue, however, was significantly greater than for visceral adipose tissue With regain of body weight there is a preferential regain of subcutaneous adipose tissue.
These data demonstrate a redistribution of abdominal adipose tissue with weight regain in anorexia nervosa subjects. This is a preview of subscription content, access via your institution.
Institute of Internal Medicine, University of Verona, Verona, Italy. Department of Medicine, Obesity Research Center, St Luke's-Roosevelt Hospital, Columbia University College of Physicians and Surgeons, New York, USA. You can also search for this author in PubMed Google Scholar.
Reprints and permissions. Zamboni, M. et al. Body fat distribution before and after weight gain in anorexia nervosa. Int J Obes 21 , 33—36 Download citation. Accepted : 20 September Issue Date : 01 January Anyone you share the following link with will be able to read this content:. Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative. European Journal of Clinical Nutrition Skip to main content Thank you for visiting nature. nature international journal of obesity paper article.
Abstract OBJECTIVE: To study abdominal fat distribution in anorexia nervosa subjects and to assess the effects of initial weight regain on abdominal fat distribution.
What allows one person to remain thin without effort but demands that another struggle to avoid gaining weight or regaining the pounds he or she has lost previously?
On a very simple level, your weight depends on the number of calories you consume, how many of those calories you store, and how many you burn up.
But each of these factors is influenced by a combination of genes and environment. Both can affect your physiology such as how fast you burn calories as well as your behavior the types of foods you choose to eat, for instance.
The interplay between all these factors begins at the moment of your conception and continues throughout your life. The balance of calories stored and burned depends on your genetic makeup, your level of physical activity, and your resting energy expenditure the number of calories your body burns while at rest.
If you consistently burn all of the calories that you consume in the course of a day, you will maintain your weight. If you consume more energy calories than you expend, you will gain weight.
Excess calories are stored throughout your body as fat. Your body stores this fat within specialized fat cells adipose tissue — either by enlarging fat cells, which are always present in the body, or by creating more of them. If you decrease your food intake and consume fewer calories than you burn up, or if you exercise more and burn up more calories, your body will reduce some of your fat stores.
When this happens, fat cells shrink, along with your waistline. To date, more than different genes have been implicated in the causes of overweight or obesity, although only a handful appear to be major players.
Genes contribute to the causes of obesity in many ways, by affecting appetite, satiety the sense of fullness , metabolism, food cravings, body-fat distribution, and the tendency to use eating as a way to cope with stress.
The strength of the genetic influence on weight disorders varies quite a bit from person to person. Having a rough idea of how large a role genes play in your weight may be helpful in terms of treating your weight problems. Genes are probably a significant contributor to your obesity if you have most or all of the following characteristics:.
Genes are probably a lower contributor for you if you have most or all of the following characteristics:. These circumstances suggest that you have a genetic predisposition to be heavy, but it's not so great that you can't overcome it with some effort.
At the other end of the spectrum, you can assume that your genetic predisposition to obesity is modest if your weight is normal and doesn't increase even when you regularly indulge in high-calorie foods and rarely exercise.
People with only a moderate genetic predisposition to be overweight have a good chance of losing weight on their own by eating fewer calories and getting more vigorous exercise more often. These people are more likely to be able to maintain this lower weight. When the prey escaped or the crops failed, how did our ancestors survive?
Those who could store body fat to live off during the lean times lived, and those who couldn't, perished. Today, of course, these thrifty genes are a curse rather than a blessing.
Not only is food readily available to us nearly around the clock, we don't even have to hunt or harvest it! In contrast, people with a strong genetic predisposition to obesity may not be able to lose weight with the usual forms of diet and exercise therapy.
Even if they lose weight, they are less likely to maintain the weight loss. For people with a very strong genetic predisposition, sheer willpower is ineffective in counteracting their tendency to be overweight.
Typically, these people can maintain weight loss only under a doctor's guidance. They are also the most likely to require weight-loss drugs or surgery. The prevalence of obesity among adults in the United States has been rising since the s. Genes alone cannot possibly explain such a rapid rise.
Although the genetic predisposition to be overweight varies widely from person to person, the rise in body mass index appears to be nearly universal, cutting across all demographic groups. These findings underscore the importance of changes in our environment that contribute to the epidemic of overweight and obesity.
Genetic factors are the forces inside you that help you gain weight and stay overweight; environmental factors are the outside forces that contribute to these problems.
They encompass anything in our environment that makes us more likely to eat too much or exercise too little. Taken together, experts think that environmental factors are the driving force for the causes of obesity and its dramatic rise.
Environmental influences come into play very early, even before you're born. Researchers sometimes call these in-utero exposures "fetal programming. The same is true for babies born to mothers who had diabetes. Researchers believe these conditions may somehow alter the growing baby's metabolism in ways that show up later in life.
After birth, babies who are breast-fed for more than three months are less likely to have obesity as adolescents compared with infants who are breast-fed for less than three months. Childhood habits often stick with people for the rest of their lives. Kids who drink sugary sodas and eat high-calorie, processed foods develop a taste for these products and continue eating them as adults, which tends to promote weight gain.
Likewise, kids who watch television and play video games instead of being active may be programming themselves for a sedentary future.
Many features of modern life promote weight gain. In short, today's "obesogenic" environment encourages us to eat more and exercise less.
And there's growing evidence that broader aspects of the way we live — such as how much we sleep, our stress levels, and other psychological factors — can affect weight as well. According to the Centers for Disease Control and Prevention CDC , Americans are eating more calories on average than they did in the s.
Between and , the average man added calories to his daily fare, while the average woman added calories a day. What's driving this trend? Experts say it's a combination of increased availability, bigger portions, and more high-calorie foods. Practically everywhere we go — shopping centers, sports stadiums, movie theaters — food is readily available.
You can buy snacks or meals at roadside rest stops, hour convenience stores, even gyms and health clubs.
In the s, fast-food restaurants offered one portion size. Today, portion sizes have ballooned, a trend that has spilled over into many other foods, from cookies and popcorn to sandwiches and steaks.
A typical serving of French fries from McDonald's contains three times more calories than when the franchise began.
A single "super-sized" meal may contain 1,—2, calories — all the calories that most people need for an entire day. And research shows that people will often eat what's in front of them, even if they're already full. Not surprisingly, we're also eating more high-calorie foods especially salty snacks, soft drinks, and pizza , which are much more readily available than lower-calorie choices like salads and whole fruits.
Fat isn't necessarily the problem; in fact, research shows that the fat content of our diet has actually gone down since the early s. But many low-fat foods are very high in calories because they contain large amounts of sugar to improve their taste and palatability.
In fact, many low-fat foods are actually higher in calories than foods that are not low fat. The government's current recommendations for exercise call for an hour of moderate to vigorous exercise a day. Our daily lives don't offer many opportunities for activity.
Children don't exercise as much in school, often because of cutbacks in physical education classes. Many people drive to work and spend much of the day sitting at a computer terminal. Because we work long hours, we have trouble finding the time to go to the gym, play a sport, or exercise in other ways.
Instead of walking to local shops and toting shopping bags, we drive to one-stop megastores, where we park close to the entrance, wheel our purchases in a shopping cart, and drive home.
The widespread use of vacuum cleaners, dishwashers, leaf blowers, and a host of other appliances takes nearly all the physical effort out of daily chores and can contribute as one of the causes of obesity. The average American watches about four hours of television per day, a habit that's been linked to overweight or obesity in a number of studies.
Data from the National Health and Nutrition Examination Survey, a long-term study monitoring the health of American adults, revealed that people with overweight and obesity spend more time watching television and playing video games than people of normal weight.
Watching television more than two hours a day also raises the risk of overweight in children, even in those as young as three years old. Part of the problem may be that people are watching television instead of exercising or doing other activities that burn more calories watching TV burns only slightly more calories than sleeping, and less than other sedentary pursuits such as sewing or reading.
But food advertisements also may play a significant role. The average hour-long TV show features about 11 food and beverage commercials, which encourage people to eat. And studies show that eating food in front of the TV stimulates people to eat more calories, and particularly more calories from fat.
In fact, a study that limited the amount of TV kids watched demonstrated that this practice helped them lose weight — but not because they became more active when they weren't watching TV. The difference was that the children ate more snacks when they were watching television than when doing other activities, even sedentary ones.
Obesity experts now believe that a number of different aspects of American society may conspire to promote weight gain. Stress is a common thread intertwining these factors.
gov Immune system defense it's official. Federal government websites often gaim in. gov or. Before Fat distribution and weight gain sensitive information, make sure you're on a federal government site. The site is secure. NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Gambacciani, M. Ciaponi, B. Cappagli, L. Gxin, L. De Simone, Abd. Orlandi, A. There were no differences in basal body weight or body fat distribution in the two groups before the study.
ich beglückwünsche, die glänzende Idee und ist termingemäß